EGFR Inhibitors
Santa Cruz Biotechnology now offers a broad range of EGFR Inhibitors. The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Upregulation of EGFR is associated with tumor progression. Abrogation of EGFR may be achieved with the use of EGFR Inhibitors with potential results in cell cycle arrest, apoptosis or dedifferentiation of cancer cells. EGFR Inhibitors offered by Santa Cruz inhibit EGFR and, in some cases, other receptor tyrosine kinases and tumor progression related proteins. View detailed EGFR Inhibitor specifications, including EGFR Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 11 to 20 of 98 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Herbimycin A | 70563-58-5 | sc-3516 sc-3516A | 100 µg 1 mg | $272.00 $1502.00 | 13 | |
Herbimycin A (CAS 70563-58-5) is a chemical compound known for its inhibitory action on the Epidermal Growth Factor Receptor (EGFR). By targeting EGFR, it interferes with crucial signaling pathways involved in cell growth and differentiation, potentially impacting various cellular processes. | ||||||
PD 168393 | 194423-15-9 | sc-222138 | 1 mg | $162.00 | 4 | |
PD 168393 (CAS 194423-15-9) is a chemical compound that acts as an inhibitor of EGFR (Epidermal Growth Factor Receptor). By targeting EGFR, it interferes with the signaling pathways associated with cell growth and proliferation. The compound's specific mechanism of action allows it to modulate EGFR function, making it a valuable tool in research and scientific investigations related to cellular signaling pathways. | ||||||
Daphnetin | 486-35-1 | sc-203022 | 10 mg | $82.00 | ||
Daphnetin (CAS 486-35-1) is a chemical compound known for its inhibitory action on EGFR (Epidermal Growth Factor Receptor). It displays the ability to regulate the function of this receptor, affecting specific cellular pathways without implying any clinical or therapeutic applications. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $112.00 $194.00 | 13 | |
Afatinib (CAS 439081-18-2) is a chemical compound known for its inhibitory action on EGFR (Epidermal Growth Factor Receptor). It interferes with EGFR signaling pathways, potentially impeding abnormal cell growth and proliferation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib (CAS 231277-92-2) is a chemical compound known for its role as an EGFR inhibitor. It functions by blocking the activity of the epidermal growth factor receptor (EGFR), a protein involved in cell growth and division. This inhibition can potentially impact various cellular processes where EGFR plays a crucial role. | ||||||
PKC-412 | 120685-11-2 | sc-200691 sc-200691A | 1 mg 5 mg | $51.00 $112.00 | 10 | |
PKC-412 is notable for its ability to selectively inhibit the activity of specific kinases, particularly those involved in cell signaling pathways. Its unique molecular architecture allows for precise interactions with target proteins, modulating their activity and influencing cellular processes. The compound demonstrates distinct binding affinities, which can lead to varied kinetic profiles in enzymatic reactions. This specificity contributes to its role in altering cellular behavior and signaling networks. | ||||||
PD 174265 | 216163-53-0 | sc-204170 | 1 mg | $160.00 | 4 | |
PD 174265 (CAS 216163-53-0) is a chemical compound known for its inhibitory action on EGFR (Epidermal Growth Factor Receptor). As an EGFR inhibitor, it modulates the activity of this receptor, which plays a crucial role in cell signaling and proliferation. This modulation may have significant effects on cellular functions related to EGFR. | ||||||
Tyrphostin 51 | 122520-90-5 | sc-200545 sc-200545A | 5 mg 25 mg | $59.00 $305.00 | ||
Tyrphostin 51 is characterized by its selective inhibition of the epidermal growth factor receptor (EGFR), showcasing a unique ability to disrupt receptor dimerization and autophosphorylation. Its structural features facilitate specific interactions with the ATP-binding site, leading to altered conformational dynamics. This compound exhibits distinct reaction kinetics, influencing downstream signaling pathways and cellular responses, thereby providing insights into receptor-mediated processes. | ||||||
Butein | 487-52-5 | sc-202510 sc-202510A | 5 mg 50 mg | $172.00 $306.00 | 8 | |
Butein acts as a potent inhibitor of the epidermal growth factor receptor (EGFR) by engaging in specific molecular interactions that prevent receptor activation. Its unique structure allows for competitive binding at the ATP site, effectively modulating the receptor's conformational state. This compound influences the kinetics of phosphorylation events, thereby altering signal transduction pathways. Butein's distinct properties contribute to its role in regulating cellular mechanisms associated with EGFR activity. | ||||||
Vatalanib Dihydrochloride | 212141-51-0 | sc-202379 sc-202379A | 5 mg 25 mg | $125.00 $374.00 | ||
Vatalanib Dihydrochloride functions as a selective antagonist of the epidermal growth factor receptor (EGFR), exhibiting unique binding characteristics that disrupt receptor dimerization. Its molecular design facilitates allosteric modulation, influencing downstream signaling cascades. The compound's interaction with key residues alters the receptor's structural dynamics, impacting the kinetics of ligand-induced activation. This specificity enhances its ability to regulate cellular responses linked to EGFR signaling pathways. | ||||||